Prologis Property Mexico SA de CV
Change company Symbol lookup
Select an option...
FBBPF Prologis Property Mexico SA de CV
NRZ New Residential Investment Corp
BOMN Boston Omaha Corp
GLD SPDR® Gold Shares
GIS General Mills Inc
GILD Gilead Sciences Inc
GGN GAMCO Global Gold, Natural Resources & Income Trust
GGN GAMCO Global Gold, Natural Resources & Income Trust
GEF Greif Inc
GE General Electric Co

Based in Mexico
Company profile

Prologis Property Mexico SA de CV is a Mexico-based real estate investment trust. The REIT provides platform of logistics and distribution facilities. The REIT manufactures, invests in and develops space for rent across, focusing on industrial real estate. Prologis Property Mexico SA de CV concentrates on assisting customers with both offshoring and near-shoring for their logistics and light manufacturing operations, as well as regional distribution to Mexico’s markets. The REIT offers approximately 190 facilities and over 780 acres of land for development.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

DaVita Clinical Research to Present New Findings at American Society of Nephrology Kidney Week 2020

9:01 am ET October 22, 2020 (PR Newswire) Print

DaVita Clinical Research (DCR) will present 14 research abstracts from company representatives and medical professionals at the American Society of Nephrology (ASN) annual Kidney Week occurring Oct. 22-25, 2020.

Amid the COVID-19 pandemic, ASN Kidney Week 2020 will convene more than 13,000 kidney care professionals from around the world in a virtual format to discuss advancements in the field of nephrology.

"We believe our commitment to pursuing life-enhancing research discoveries is helping accelerate transformation in kidney care," said Dr. Steven Brunelli, vice president and medical director of health economics and outcomes research for DCR. "During these unprecedented times, Kidney Week continues to be a vital convening platform for clinical experts to share meaningful insights and potential real-world solutions that could improve the well-being of medically complex kidney disease patients."

DaVita researchers will report on findings from multiple retrospective studies, with a particular focus on how COVID-19 affects dialysis patients, home dialysis treatments and chronic kidney disease progression.

This year's poster and presentation titles include:

DaVita Clinical Research

-- Assessment of a Laboratory-Based SARS-CoV-2 Antibody Test Among Hemodialysis Patients: A Quality Improvement Initiative

-- Management of Secondary Hyperparathyroidism Among Patients Who Transition from Daily At-Home to 3X Weekly Oral Cinaclect Given In-Center

-- Associations Between Antimicrobial Barrier Cap Use and Outcomes Among Hemodialysis Patients Using a Central Venous Catheter

-- Urgent Start Peritoneal Dialysis and Outcomes

-- Longitudinal Assessment of Random Variability in ICH-CAHPS Scores

-- Use of Predictive Analytics to Inform Integrated Care Programs to Reduce Hospitalizations Among Hemodialysis Patients

-- Exploration of Racial Disparities in the Kidney Transplant Process Among Dialysis Patients

-- Use of Incremental Peritoneal Dialysis: Impact on Clinical Outcomes and Quality-of-Life Measures

-- Patterns of Hospital Admissions Among Patients with Chronic Kidney Disease

-- Development and Validation of a Predictive Model to Identify Patients with Undiagnosed Chronic Kidney Disease

-- Inpatient Dialysis Provider Type and Duration of Hospital Admissions of Dialysis Patients

-- Strategies to Prevent Infection-Related Losses in U.S. Peritoneal Dialysis Programs by More Actionable Predictive Data Reporting

-- Blood Pressure Telemonitoring in Large U.S. Peritoneal Dialysis Population

-- Impact of the COVID-19 Pandemic on Virtual Care in Home Dialysis

ASN Kidney Week attendees can view ePosters and pre-recorded presentations from DCR and DaVita Kidney Care clinical leaders at beginning Oct. 22. DaVita representatives will be available to discuss appropriate opportunities in the Kidney Week digital exhibit hall. Live updates will be shared throughout the meeting on Twitter at @DaVitaDoc and @DaVitaResearch. Attendees, as well as those who cannot participate in the virtual sessions, are encouraged to join or view the conversation by using #KidneyWk.

To learn more about DCR, visit

About DaVita Clinical Research DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is the research arm of DaVita. DCR innovates through retrospective research aimed at improving clinical outcomes. DCR assists pharmaceutical and medical device companies in the design, recruitment and completion of clinical trials using its renal research site network. To learn more about DCR, visit

About DaVita Inc. DaVita Inc. (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of June 30, 2020, DaVita served 205,300 patients at 2,795 outpatient dialysis centers in the United States and operated 287 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit

Contact InformationMedia:Halie Peddle(303)

View original content to download multimedia:

SOURCE DaVita Clinical Research

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.